Bristol-Myers Squibb

Overview

US pharma major that announced a $15.2 billion asset-exchange collaboration with Henlius in May 2026, combining immuno-oncology and autoimmunity programs and five joint discovery projects. Bristol Myers Squibb announced a $15.2 billion strategic collaboration with Henlius in May 2026, timed to coincide with the Trump-Xi summit, exchanging four immuno-oncology assets from Henlius for four autoimmunity assets from BMS. The BMS-Henlius collaboration includes five joint discovery programs to be conducted at Henlius wet labs, enabling BMS to achieve faster clinical proof-of-concept in China using Henlius's development capacity. (Segment 1 (00:00-05:00)) Bristol-Myers Squibb has maintained FAIR-structured data for at least seven years, enabling them to build a global cell line model across multiple programs and use Bayesian optimization to reduce new molecule process development to as few as five targeted experiments. (Segment 10 (45:00-50:00))